Lisa
07-06-2005, 11:20 AM
Friends,
I wrote Walter Carney again, asking him the questions from Sue, SusanAnne Steph. Here is my partial e-mail to him and his very generous reply.
-------------------------------------------------------------------------------------
From Sue: This serum test is currently approved for only metastatic disease correct? I'm not quite clear why it wouldn't be useful to monitor earlier stage cancer in conjunction with tumor markers? Couldn't our oncologists order the test "off label" just like some did with Herceptin?
From SusanAnne: For we who have not previously had herceptin could the bayer test be of some use. I know we have talked about this alot but it is important. For those of us early stage her2+++ that finished chemo more than 1 year ago could the bayer serum test give some indication of whether or not we should strongly consider herceptin now?
From Steph N: The FISH test gives a lot of detailed information about the HER2 activity in a patient. Does the Bayer or other test also measure for the same components? Or just give the level of HER2 present in the blood?
Hi Lisa. I'm glad my comments could be helpful. I hope the following helps.
Questions from Sue.
Yes, the test is cleared by the US FDA for the management and monitoring of serum HER-2/neu in patients with metastatic breast cancer.
Bayer is currently conducting clinical trials to determine if measuring serum
HER-2/neu in the adjuvant setting will have clinical utility. if our studies
indicate that it can be, then we will pursue permission from the US FDA for approval to use it for that purpose.
My hope is that someday, baseline serum HER-2/neu values will be obtained at the Diagnosis of primary breast cancer and that patients will be monitored for life. however, before that can happen it is the responsibility of Bayer to prove to the FDA that such a test is safe and effective and can be used for that indication.
Bayer does not endorse the use of tests " off label". As we all know, the FDA is there to protect us and ensure that we are protected from false claims of drugs and tests. The FDA looks for good science and is not a barrier but a very helpful agency that works with companies like Bayer to deliver the best tests that are safe and effective. In getting the serum HER-2/neu test cleared by the FDA I found them to be highly professional and helpful. In many cases "off label" does harm.
SusanAnne. Currently, Bayer is involved in clinical trials to determine if
measuring serum HER-2/neu in the adjuvant setting will have clinical value. My hope is that serum HER-2/neu as a Biomarker for HER-2/neu positive tumors will be used one day to help determine who should receive anti-HER-2/neu therapies such as Herceptin and the new anti-HER-2/neu drug in clinical trials by GSK called Lapatinib. We are very hopeful that many of the anti-HER-2/neu drugs in development will be even more helpful than Herceptin.
Steph N.
The FISH test is only preformed on the primary breast tumor. The FISH test
tells us how many copies of the HER-2/neu gene are in the cell. The gene or the HER-2/neu DNA then makes RNA. RNA makes the HER-2/neu protein which sits on the surface of the cell. Herceptin attacks the HER-2/neu protein on the cell surface . So the FISH test and IHC test only tell us the HER-2/neu status of the original breast cancer. Later in life when the HER-2/neu positive breast cancer has spread to other parts of the body ( metastatic breast cancer) the FISH and IHC tests aren't used. Therefore the only test that can monitor changes in the circulating form of HER-2/neu test is the serum HER-2/neu test. The serum HER-2/neu test is the ONLY test FDA cleared that can actually monitor changes in the HER-2/neu positive tumor by measuring changes of the protein in the serum.
So FISH measures the gene, IHC measures the internal portion of the HER-2/neu protein in the primary tumor. The serum HER-2/neu test measures the external portion of the HER-2/neu protein that sits on the cell ( and is released into the blood stream for reasons we do not yet understand) and that is actually the place where Herceptin binds and attacks the cancer cell. The FISH test tells us information about the number of HER-2/neu genes in the primary tumor, which is removed by surgery. FISH and IHC tell nothing about the changing status of a HER-2/neu tumor once the primary tumor is removed and tells us nothing about the tumors that cause metastatic breast cancer.
Lisa, I hope these are informative and helpful. Since I invented the serum
HER-2/neu test back in the mid 80's, i see lots of value for this test from the time of breast cancer diagnosis to metastatic cancer, however, we at Bayer still have plenty of research to do to convince the FDA, oncologists and patients that serum HER-2/neu will have value pre-metastatic breast cancer. By the way we have developed other tests, for instance a test that measures the external portion of EGFR in the serum .
let me know if these explanations are clear or if you have any additional
questions.
walt
I wrote Walter Carney again, asking him the questions from Sue, SusanAnne Steph. Here is my partial e-mail to him and his very generous reply.
-------------------------------------------------------------------------------------
From Sue: This serum test is currently approved for only metastatic disease correct? I'm not quite clear why it wouldn't be useful to monitor earlier stage cancer in conjunction with tumor markers? Couldn't our oncologists order the test "off label" just like some did with Herceptin?
From SusanAnne: For we who have not previously had herceptin could the bayer test be of some use. I know we have talked about this alot but it is important. For those of us early stage her2+++ that finished chemo more than 1 year ago could the bayer serum test give some indication of whether or not we should strongly consider herceptin now?
From Steph N: The FISH test gives a lot of detailed information about the HER2 activity in a patient. Does the Bayer or other test also measure for the same components? Or just give the level of HER2 present in the blood?
Hi Lisa. I'm glad my comments could be helpful. I hope the following helps.
Questions from Sue.
Yes, the test is cleared by the US FDA for the management and monitoring of serum HER-2/neu in patients with metastatic breast cancer.
Bayer is currently conducting clinical trials to determine if measuring serum
HER-2/neu in the adjuvant setting will have clinical utility. if our studies
indicate that it can be, then we will pursue permission from the US FDA for approval to use it for that purpose.
My hope is that someday, baseline serum HER-2/neu values will be obtained at the Diagnosis of primary breast cancer and that patients will be monitored for life. however, before that can happen it is the responsibility of Bayer to prove to the FDA that such a test is safe and effective and can be used for that indication.
Bayer does not endorse the use of tests " off label". As we all know, the FDA is there to protect us and ensure that we are protected from false claims of drugs and tests. The FDA looks for good science and is not a barrier but a very helpful agency that works with companies like Bayer to deliver the best tests that are safe and effective. In getting the serum HER-2/neu test cleared by the FDA I found them to be highly professional and helpful. In many cases "off label" does harm.
SusanAnne. Currently, Bayer is involved in clinical trials to determine if
measuring serum HER-2/neu in the adjuvant setting will have clinical value. My hope is that serum HER-2/neu as a Biomarker for HER-2/neu positive tumors will be used one day to help determine who should receive anti-HER-2/neu therapies such as Herceptin and the new anti-HER-2/neu drug in clinical trials by GSK called Lapatinib. We are very hopeful that many of the anti-HER-2/neu drugs in development will be even more helpful than Herceptin.
Steph N.
The FISH test is only preformed on the primary breast tumor. The FISH test
tells us how many copies of the HER-2/neu gene are in the cell. The gene or the HER-2/neu DNA then makes RNA. RNA makes the HER-2/neu protein which sits on the surface of the cell. Herceptin attacks the HER-2/neu protein on the cell surface . So the FISH test and IHC test only tell us the HER-2/neu status of the original breast cancer. Later in life when the HER-2/neu positive breast cancer has spread to other parts of the body ( metastatic breast cancer) the FISH and IHC tests aren't used. Therefore the only test that can monitor changes in the circulating form of HER-2/neu test is the serum HER-2/neu test. The serum HER-2/neu test is the ONLY test FDA cleared that can actually monitor changes in the HER-2/neu positive tumor by measuring changes of the protein in the serum.
So FISH measures the gene, IHC measures the internal portion of the HER-2/neu protein in the primary tumor. The serum HER-2/neu test measures the external portion of the HER-2/neu protein that sits on the cell ( and is released into the blood stream for reasons we do not yet understand) and that is actually the place where Herceptin binds and attacks the cancer cell. The FISH test tells us information about the number of HER-2/neu genes in the primary tumor, which is removed by surgery. FISH and IHC tell nothing about the changing status of a HER-2/neu tumor once the primary tumor is removed and tells us nothing about the tumors that cause metastatic breast cancer.
Lisa, I hope these are informative and helpful. Since I invented the serum
HER-2/neu test back in the mid 80's, i see lots of value for this test from the time of breast cancer diagnosis to metastatic cancer, however, we at Bayer still have plenty of research to do to convince the FDA, oncologists and patients that serum HER-2/neu will have value pre-metastatic breast cancer. By the way we have developed other tests, for instance a test that measures the external portion of EGFR in the serum .
let me know if these explanations are clear or if you have any additional
questions.
walt